ASCO Abstracts

Temsirelimus in Metastatic RCC: Safety and Efficacy in Patients Previously Treated with VEGF-targeted Therapy
Laura S. Wood RN MSN, Ronald M. Bukowski, Robert Dreicer, Paul Elson, Jorge A. Garcia, Timothy D. Gilligan, Tarek M. Mekhail and Brian I. Rini

Metastatic renal cell carcinoma (mRCC) with sarcomatoid component treated with VEGF-targeted therapy.
A. R. Golshayan, S. George, D. Heng, P. Elson, L. Wood, T. Mekhail, J. A. Garcia, H. Aydin, M. Zhou, R. M. Bukowski, B. I. Rini; Cleveland Clinic, Cleveland, OH

Phase II of rebeccamycin in refractory small cell lung cancer.
Afshin Dowlati, Tare Mekhail, et al.

Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (mCCRCC) patients (pts) treated with sunitinib
Faber, Vaziri, Wood, Nemec, Elson, Garcia, Rini, Bukowski, Ganapathi, M., Ganapathi, R.

Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (Pts)
Saby George, Patricia Rayman, Soumika Biswas, Jennifer Ko, Laura Wood, Tashi Smith-Williams, Paul Elson, Brian I. Rini, Ronald M. Bukowski, James Finke

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736)
Brian Rini, Joan Schiller, John Fruehaufl, Ezra Cohen, Jamal Tarazi, Brad Rosbrook, Alejandro Ricart, Anthony Olszanski, Sinil Kim, Jean-Philippe Spano

Jeff Smerage, Gerald Doyle, Craig Miller, Thomas Budd, Madeline Repollet, Leon WMM Terstappen, Daniel Hayes

Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial
Session J Garcia, P Triozzi, S Smith, BI Rini, T Gilligan, D Peereboom, P Elson, S Hoddick, E Klein, R Dreicer
Phase II Trial of Sorafenib in Advanced Carcinoma of the Urothelium (E 1804): A Trial of the Eastern Cooperative Oncology Group
Robert Dreicer, Hailun Li, Mark Stein, Robert DiPaola, Michael Eleff, Bruce J. Roth, George Wilding

Sunitinib and bevacizumab in advanced solid tumors: a phase I trial.

A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab

Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsiroliimus

Phase II trial of peri-operative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer.
Rodriguez CP, Adelstein DJ, Rybicki LA, Rice TW, Videtic GMM, Saxton JR, Murthy SC, Mason DP, Ives DI

Poster Presentations

Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group
Robert Dreicer, Hailun Li, Mark Stein, Robert DiPaola, Michael Eleff, Bruce J. Roth, George Wilding

Clinical significance of serial measurement of Bcl-2 expression and apoptosis in circulating tumor cells in metastatic breast cancer patients undergoing treatment
Jeff Smerage, Gerald Doyle, Craig Miller, Thomas Budd, Madeline Repollet, Leon WMM Terstappen, Daniel Hayes

A phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer
Rodriguez CP, Adelstein DJ, Rybicki LA, Rice TW, Videtic GMM, Saxton JR, Murthy SC, Mason DP, Ives DI

Poster Discussion

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736)
Brian Rini, et al.